ZymoGenetics


PIPELINE OVERVIEW | PIPELINE | RECOTHROM™
OUTLICENSED PRODUCTS | CANDIDATE BACKGROUNDERS

 
 
Select Program: 
Select Indication: 
R & D
Pre-Clinical IND
CLINICAL
Phase 1 Phase 2 Phase 3 Pre-Registration
POST-APPROVAL
Registration Marketed
Therapeutic Candidate Target Indication
RECOTHROM Surgical Hemostasis 
Marketed
Atacicept Systemic Lupus Erythematosus 
Phase 2/3
Atacicept Multiple Sclerosis 
Phase 2
Atacicept Rheumatoid Arthritis 
Phase 2
IL-21 Metastatic Melanoma 
Phase 2
IL-21 & Nexavar Renal Cell Carcinoma 
Phase 2
Atacicept Chronic Lymphocytic Leukemia 
Phase 1
Atacicept Multiple Myeloma 
Phase 1
Atacicept Non-Hodgkin's Lymphoma 
Phase 1
IL-21 Metastatic Renal Cell Carcinoma 
Phase 1
IL-21 & Erbitux Colorectal cancer 
Phase 1
IL-21 & Rituxan Non-Hodgkin's Lymphoma 
Phase 1
PEG-interferon lambda Hepatitis C 
Phase 1
IL-17RC Rheumatoid Arthritis, IBD 
Pre-Clinical


Back to top.Back to top

Home Site Map Contact Terms & Conditions Glossary
copyright © 2003 - 2008 ZymoGenetics